Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 13 Feb 2026 for Enanta Pharmaceuticals INC.
Insider track record
Disclosed buys
0
Disclosed sells
0
Signal history
Matthew Paul Kowalsky: trading record in brief
Matthew Paul Kowalsky discloses dealings in 3 companies, chiefly Protara Therapeutics, Inc., Enanta Pharmaceuticals Inc and Sigilon Therapeutics, Inc. Over a trading history stretching from 30 June 2017 to 12 February 2026, the count stands at 8 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 13 February 2026, the filings show a share grant in Enanta Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Matthew Paul Kowalsky
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
4,175 shares0Common StockSEC:0002064832-26-000016:1
1,902 shares@ US$14.25100.0% of flowCommon StockSEC:0002064832-26-000016:2
1,318 shares0Common StockSEC:0002064832-26-000016:0
1,925 sharesCommon StockSEC:0001415889-23-012133:0
2,448 shares@ US$1.9318.4% of flowCommon StockSEC:0001171843-19-000065:0
10,000 shares@ US$1.6241.5% of flowCommon StockSEC:0001171843-18-004990:0
3,934 shares@ US$1.3012.7% of flowCommon StockSEC:0001171843-18-000083:0
10,000 shares@ US$1.3033.6% of flowCommon StockSEC:0001171843-17-003953:0
8 of 8 declarations
